Intellia Therapeutics Head office building

Press Releases

Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy

Read More

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress

Read More


More events are coming soon.


OUR COMMITMENT Intellia’s objective is to build a sustainable company delivering on our commitment to the patients we serve, our employees, community, environment and shareholders.

We believe Environmental, Social and Governance (ESG) principles support long term value creation. Throughout this report, we have highlighted our approach to managing risk and taking advantage of opportunities in key ESG areas the areas that are most relevant to the long term sustainability of our company.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.